 |
5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine |
|---|---|
| Trade Name | |
| Orphan Indication | Primary central nervous system lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2016-11-21 00:00:00 |
| Sponsor | PIQUR Therapeutics AG;Hochbergerstrasse 60C, CH-4057 Basel; |
